Clinical trial · Interventional
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gecacitinib Hydrochloride Tablets | Drug | — | UNRESOLVED |
| ZG005 for Injection | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Part 1: Plan A
- description
- ZG005（20mg/kg Q3W）+Gecacitinib（Gecacitinib is administered continuously until the end of treatment）
- interventionNames
- Biological: ZG005 for Injection
- Drug: Gecacitinib Hydrochloride Tablets
- type
- EXPERIMENTAL
- label
- Part 1: Plan B
- description
- ZG005（20mg/kg Q3W）+Gecacitinib（Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21）
- interventionNames
- Biological: ZG005 for Injection
- Drug: Gecacitinib Hydrochloride Tablets
Primary outcomes (1)
- measure
- Objective response rate (ORR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Fully understand this study and voluntarily sign the ICF； * Age ≥18 at ICF signing, regardless of gender； * Histologically confirmed relapsed or refractory lymphoma. Exclusion Criteria: * Lymphoma with known CNS involvement； * Severe cardiovascular/cerebrovascular diseases. * Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
References
Publications (0)
Data not yet available